Table 1.

Summary of variables before BMT based on Barrett’s status (N=228)

Covariate	Levels	Barrett’s status after BMT		P-value
		Yes (n=98)	No (n=130)
Age at diagnosis (year) median (range)	–	67 (31 - 103)	67 (28 - 85)	.52
Tumor length at diagnosis (cm) median (range)	–	5 (1 - 13)	5 (1 - 13)	.81
Gender	Male	93(94.9%)	115(88.5%)	.09
	Female	5(5.1%)	15(11.5%)
Siewert class	Esophagus	13(13.3%)	3(2.3%)	<.0001
	AEG1	58(59.2%)	55(42.3%)
	AEG2	26(26.5%)	72(55.4%)
	NA	1(1%)	0
Tumor Histology Subtype	SRC	16(16.3%)	19(14.6%)	.72
	M	1(1%)	2(1.5%)
	M&SRC	3(3.1%)	5(3.8%)
	NE	3(3.1%)	1(0.8%)
	NOS	75(76.5%)	103(79.2%)
Chronic GERD history	Yes	60(61.2%)	78(60%)	. 85
	No	38(38.8%)	52(40%)
Barrett’s before BMT (biopsy)	Yes	50(51%)	18(13.9%)
	No	48(49%)	112(86.2%)	<.0001
Barrett’s length before BMT(endoscopy appearance)	LS≥3cm	38(76%)	14(63.6%)
	SS<3cm	12(24%)	8(36.4%)	<0.0001
Highest dysplasia before BMT (biopsy)	HG	34(34.7%)	12(9.2%)	<.0001
	LG	10(10.2%)	2(1.5%)
	None	54(55.1%)	116(89.2%)
Baseline T-staging	T1	3(3%)	3(2.3%)	.27
	T2	15(15.3%)	10(7.7%)
	T3	74(75.5%)	109(83.8%)
	T4	3(3%)	3(2.3%)
	TX	3(3.1%)	5(3.8%)
Baseline N-staging	N0	36(36.7%)	51 (39.2%)	.37
	N1	54(55.1%)	62(47.7%)
	N2	3(3.1%)	10(7.7%)
	N3	1(1%)	2(1.5%)
	NX	4(1.1%)	5(3.8%)
Baseline M-staging	M0	88(89.8%)	110(84.6%%	.12
	M1	6(6.1%)	17(13.1%)
	MX	4(4.1%)	3(2.3%)
Baseline staging	I	9(9.1%)	5(3.8%)	.07
	II-III	80(81.6%)	105(80.8%)
	IV	6(6.1%)	17(13.1%)
	NA	3 (3.1%)	3(2.3%)

Abbreviations: BMT: bimodality therapy, GERD: gastroesophageal reflux disease, M: mucinous, NE: neuroendocrine; NOS: not otherwise specified; NA: not available, SRC: signet ring cell